secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2021-07-08T23:59:59+00:00
Accession:  0001564590-21-036032
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea Biotherapeutics appoints Jonathan Alspaugh as CFO effective July 6, 2021
-------------------------------------------------------------------------------

- Jonathan Alspaugh (38) named CFO; was Managing Director at Evercore's Corporate Advisory business from April 2013 to June 2021.
- Annual base salary of $400,008; eligible for cash bonus up to 40% of base salary based on performance criteria.
- Granted option to purchase 160,000 shares of common stock at closing price on July 6, 2021.
- Option vests 1/4th after one year and 1/48th monthly thereafter, subject to continued service.
- Company entered standard indemnification agreement with Alspaugh.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000156459021036032/0001564590-21-036032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000156459021036032/agle-8k_20210708.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-036032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer